Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,734,808
  • Shares Outstanding, K 599,701
  • Annual Sales, $ 23,747 M
  • Annual Income, $ 8,394 M
  • 60-Month Beta 1.11
  • Price/Sales 5.12
  • Price/Cash Flow 11.22
  • Price/Book 11.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 3.47
  • Number of Estimates 9
  • High Estimate 3.66
  • Low Estimate 3.31
  • Prior Year 3.69
  • Growth Rate Est. (year over year) -5.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
188.78 +8.41%
on 10/02/19
204.90 -0.12%
on 10/14/19
+9.19 (+4.70%)
since 09/13/19
3-Month
173.12 +18.22%
on 07/26/19
211.90 -3.42%
on 08/13/19
+28.54 (+16.20%)
since 07/15/19
52-Week
166.30 +23.07%
on 05/15/19
211.90 -3.42%
on 08/13/19
+9.07 (+4.64%)
since 10/15/18

Most Recent Stories

More News
Amgen (AMGN) Gains But Lags Market: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $204.66, marking a +0.87% move from the previous day.

AMGN : 204.66 (+0.87%)
Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP(TM) Team

Amgen (NASDAQ:AMGN) today announced the expansion of Myeloma MVP(TM), a national initiative to help myeloma patients and their care teams create their Most Valuable Plan. In its second year, Myeloma MVP...

AMGN : 204.66 (+0.87%)
Lilly Gets FDA Approval for New Oral Tablets for Migraine

Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.

LLY : 109.70 (+1.67%)
PFE : 36.50 (+0.55%)
AMGN : 204.66 (+0.87%)
TEVA : 6.97 (+3.57%)
Roche Announces Positive Late-Stage Data on Rituxan in PV

Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.

NVS : 86.70 (+0.90%)
RHHBY : 36.2100 (+0.53%)
BMY : 51.83 (+0.52%)
AMGN : 204.66 (+0.87%)
SmarTrend Watching for Potential Pullback in Shares of Amgen Inc After 2.54% Gain

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $199.98 to a high of $203.87. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $199.32...

AMGN : 204.66 (+0.87%)
Top Research Reports for Toyota, Amgen & TJX

Top Research Reports for Toyota, Amgen & TJX

TM : 136.87 (+1.33%)
TJX : 58.48 (+0.62%)
NSC : 180.71 (+1.22%)
MS : 42.53 (+0.66%)
BCE : 49.02 (+0.43%)
AMGN : 204.66 (+0.87%)
Alexion (ALXN) Collaborates With Stealth BioTherapeutics

Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

AMGN : 204.66 (+0.87%)
ALXN : 104.81 (+3.42%)
EIDX : 36.23 (-1.41%)
MITO : 6.91 (+0.88%)
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates

Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.

LLY : 109.70 (+1.67%)
ALXN : 104.81 (+3.42%)
AMGN : 204.66 (+0.87%)
Amgen (AMGN) Gains But Lags Market: What You Should Know

Amgen (AMGN) closed the most recent trading day at $196.69, moving +0.31% from the previous trading session.

AMGN : 204.66 (+0.87%)
Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh

The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa. Through a grant from the Richard King Mellon Foundation, the region's students will become...

AMGN : 204.66 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 206.22
1st Resistance Point 205.44
Last Price 204.66
1st Support Level 203.24
2nd Support Level 201.82

See More

52-Week High 211.90
Last Price 204.66
Fibonacci 61.8% 194.48
Fibonacci 50% 189.10
Fibonacci 38.2% 183.72
52-Week Low 166.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar